Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study
| العنوان: | Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study |
|---|---|
| المؤلفون: | Nathalie Ausias, Patrice Vanelle, Fabrice Barlesi, Roch Giorgi, Marc Montana, Mathieu Peretti, Marie Eve Garcia, François Cavaille |
| المساهمون: | Dupuis, Christine, Oncopharma (Hôpital de la Timone [CHU - APHM]), Hôpital de la Timone [CHU - APHM] (TIMONE), Oncologie multidisciplinaire et innovations thérapeutiques [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] (BiosTIC ), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Chimie Radicalaire (ICR), Aix Marseille Université (AMU)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)- Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU) |
| المصدر: | Tumori Tumori, 2021, 107 (1), pp.32-38. ⟨10.1177/0300891620926244⟩ Tumori, Casa Editrice Ambrosiana, 2020, pp.030089162092624. ⟨10.1177/0300891620926244⟩ |
| بيانات النشر: | SAGE Publications, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, medicine.drug_class, [SDV]Life Sciences [q-bio], Pembrolizumab, Antibodies, Monoclonal, Humanized, real-life population, Monoclonal antibody, B7-H1 Antigen, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, In patient, 030212 general & internal medicine, Lung cancer, non-small cell lung cancer, Aged, biology, business.industry, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Programmed Cell Death 1 Receptor, Progression-Free Survival, 3. Good health, [SDV] Life Sciences [q-bio], Treatment Outcome, 030220 oncology & carcinogenesis, biology.protein, Female, Non small cell, Antibody, business |
| الوصف: | Background: Pembrolizumab, a humanized immunoglobulin monoclonal antibody directed against the programmed cell death 1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. Aim: To investigate the efficacy and safety of first-line pembrolizumab for patients with non-small cell lung cancers (NSCLCs) in clinical practice. Methods: In this observational monocentric retrospective study, 38 patients with PD-L1 >50% were enrolled between November 2017 and November 2018. Results: The global median overall survival was 11.08 months (95% confidence interval [CI], 5.98–not reached) and the global median progression-free survival was 6 months (95% CI, 3–not reached). In the univariate analysis, clinical performance status score and the development of immune-related adverse events were the only 2 clinical factors significantly correlated with overall survival. Conclusion: The results of the present study suggest that pembrolizumab seems less effective in the real-life population than in the pivotal clinical trials in patients with NSCLC but remains an effective treatment option for patients with NSCLC. Longer follow-up is needed. |
| وصف الملف: | application/pdf |
| تدمد: | 2038-2529 0300-8916 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2acd02fc1ef298331458397d0b76bee7Test https://doi.org/10.1177/0300891620926244Test |
| حقوق: | EMBARGO |
| رقم الانضمام: | edsair.doi.dedup.....2acd02fc1ef298331458397d0b76bee7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20382529 03008916 |
|---|